Internal medicine

Vitamin K antagonist

Atrial fibrillation

Cardiology

Warfarin

Rivaroxaban

Cardioversion

valvular heart disease

Anesthesia

Medicine

EP Europace

CV Cardiovascular CYP Cytochrome P (CYP) Unfractionated heparin ULN Upper limit of normal VENTURE-AF Active-controlled multi-center study with blind-adjudication designed to evaluate the safety of uninterrupted Rivaroxaban and uninterrupted vitamin K antagonists in subjects undergoing catheter ablation for non-valvular Atrial Fibrillation VHD Valvular heart disease VKA Vitamin K antagonist VTE Venous thromboembolic event WOEST What is the Optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting X-VeRT Explore the efficacy and safety of once daily oral rivaroxaban for the prevention of cardiovascular events in patients with non-valvular atrial fibrillation scheduled for cardioversion a SmPC: 110 mg BID if age > _80 years, concomitant verapamil (both based on pharmacokinetics/pharmacodynamics analyses; not studied in this setting).b Not specifically studied, follow-up data available up to 12 months in phase III trial.c SmPc: 20 mg QD in patients at high risk of recurrence.2021 EHRA Practical Guide on the use of NOACs AF, atrial fibrillation; CrCl, creatinine clearance; INR, international normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; NSAID, non-steroidal anti-inflammatory drug; TIA, transient ischaemic attack; VKA, vitamin K antagonist.For frequency of visits: see Figure 3.

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation